Feuerstein's Biotech-Stock Mailbag: Elan
If you assume that Tysabri peak sales are cut in half, then based on Davis' math, the drug is worth about $7 a share to Elan. If Tysabri's sales are cut by a third, it's $9 a share in value.
Either way, that works out to an Elan stock price, excluding bapineuzumab, of $10-$12 a share -- a very, very rough guesstimate, for sure. Thursday night, tthe stock was trading at $11.55.
If the market is overreacting to the Tysabri-PML news because new cases of the brain infection were expected, Tysabri sales may remain relatively unaffected. But even if that's the case, I still think Elan is only worth $18 to $22 a share.
More on Elan from Stanley W., who wrote:
"I don't understand how Kelly Martin could be so bullish on bapineuzumab based on this data. Did he mislead us all?"Kelly Martin, Elan's CEO, has a BIG credibility problem with Wall Street. Without naming names, let's just say that I saw a couple of Elan's largest institutional shareholders at the ICAD conference Tuesday night, and they looked like they wanted to take Martin into an alley and, well, you get the idea. In an interview with CNBC Wednesday morning, Martin tried to blame Elan's selloff on too-high expectations and investors who want simple answers to complex questions. That's laughable. It was Martin, himself, who set those high expectations for bapineuzumab, and the data aren't difficult at all to understand. And it's Martin who fostered an arrogant, insular culture at Elan where friends were rewarded and anyone who dared question the company was frozen out. Now he wants to blame investors for the bapineuzumab fiasco? How lame. And now, Martin has an even bigger problem on his hands because few investors will give him the benefit of the doubt when he tries to soothe investor nerves about Tysabri.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV